CVE-2022-22960 (VMware Multiple Products Privilege Escalation)

What Makes This Vulnerability Dangerous in VMware Products

CVE-2022-22960 is dangerous because it turns a permissioning weakness inside support scripts into a path to higher privilege. In products that sit close to authentication, orchestration, or admin workflows, that kind of flaw can let an attacker move from limited access to control over sensitive functions.

The key security issue is not just that code exists in a privileged product, but that the affected scripts are trusted enough to influence administrative behaviour. When permissions are wrong, an attacker does not need to “break” the product in a dramatic way, they can abuse its own trust boundaries to gain more authority than intended.

How Organisations Determine Exposure

Exposure starts with knowing where the vulnerable VMware products are deployed, who administers them, and whether they are reachable from untrusted networks. Asset inventory matters because privileged enterprise tools are often spread across multiple environments, teams, and subsidiaries, so a single missed instance can remain exploitable long after the main platform is patched.

Organisations should treat vendor advisories and authoritative vulnerability records as the source of truth for version-specific remediation details. For broader prioritisation and validation, use the NIST National Vulnerability Database and the CVE Program to confirm the identifier, track disclosures, and align internal exposure management with public vulnerability references.

Where the affected system is internet-facing or reachable by broad administrative networks, the practical risk increases because exploitation can be attempted without deep internal foothold. In those cases, exposure review should include ingress paths, administrative access routes, and any downstream systems that inherit trust from the vulnerable product.

Remediation and Compensating Controls

The first goal is to remove the vulnerable version or configuration as soon as the vendor guidance allows. Until then, compensating controls should reduce the chance that the affected script path can be abused, especially by limiting who can reach the management plane and tightening the privileges of adjacent administrative accounts.

Where patching is delayed, organisations should reduce the blast radius with segmentation, restricted administrative access, and heightened change control around the VMware environment. For vulnerability prioritisation and remediation discipline, Vulnerability Management Guide is a useful companion for understanding how KEV-listed issues should move quickly through scope, verification, and remediation workflows.

Because this is a privilege escalation flaw, compensating controls are most effective when they reduce the attacker’s ability to transition from a foothold into administrative control. That means limiting local admin reach, monitoring privileged activity around the product, and reviewing any automation that depends on the affected scripts.

Detection and Post-Exploitation Review

Detection should focus on unexpected privilege changes, unusual administrative sessions, and activity that suggests script abuse rather than normal operator behaviour. A confirmed exploit may not leave obvious malware, so logs and configuration changes are often more important than file-based indicators.

After patching, organisations should review whether the product was already used as a stepping stone into higher privilege, adjacent management systems, or identity-connected services. If the vulnerable environment had administrative credentials, tokens, or sessions available to it, those should be treated as potentially exposed and reviewed for rotation or reissue where appropriate.

For attack-pattern mapping, the MITRE ATT&CK Enterprise Matrix helps teams think about privilege escalation, lateral movement, and follow-on credential abuse as part of the compromise review.

Risk and Threat Considerations

This vulnerability matters because privilege escalation in a management product can quickly become environment-wide control. If an attacker can abuse trusted scripts to elevate access, the next step is often broader administrative compromise, configuration tampering, or movement into connected systems.

Failure mechanism: Improper permissions allow a lower-privileged attacker to invoke or influence trusted support scripts in a way that yields elevated execution or administrative authority.

Impact: The attacker may gain control over the VMware platform, use it to reach other systems, or abuse its privileged position to support persistence and lateral movement.

Practitioner Guidance

What to watch for: Treat any KEV-listed privilege escalation issue in a management product as a high-priority verification event, not just a patch task. The important question is whether the product was reachable, whether privileged actions were observed, and whether dependent credentials or sessions need to be reconsidered.

Practitioner takeaway: For trusted admin platforms, privilege escalation is often an identity and access problem as much as a software defect, so remediation should include both patching and review of privileged exposure.

Related resources from NHI Mgmt Group

• CVE-2023-41992 (Apple Multiple Products Kernel Privilege Escalation)
• CVE-2018-19323 (GIGABYTE Multiple Products Privilege Escalation)
• CVE-2018-19321 (GIGABYTE Multiple Products Privilege Escalation)
• CVE-2022-26923 (Microsoft Active Directory Domain Services Privilege Escalation)